Enanta Pharmaceuticals Inc (ENTA)

[stockbettor]

Early access to G/P in UK

UK patients get early access to AbbVie’s hepatitis regimen
11th May 2017

The positive scientific opinion by the Medicines and Healthcare Products Regulatory Agency enables the regimen to be accessed by adults with compensated cirrhosis and at least one of the following: GT 1, 4, 5 or 6 infection and prior treatment with an NS5A inhibitor; GT 2, 3, 5 or 6 infection and chronic kidney disease stage 4 or 5; or GT 3 infection previously treated with peg-interferon, ribavirin and/or sofosbuvir

http://www.pharmatimes.com/news/uk_patients_get_early_access_to_abbvies_hepatitis_regimen_1192670?utm_medium=nl&utm_source=internal&mrkid=649348&mkt_tok=eyJpIjoiWVdZd1pXSXhZbU01TldFNCIsInQiOiJyVUxWNzNQNUVEckd0OWt0bUxTRWVaVjl0UDkzdzVJd1VDQUtWUG5Da2tWUTh4QnphWmhENitDTlJaMnVrdTZuaVdaRXVmdU1sU3JveTRTVnJqWlc0SU5Cam9GaUJlXC9JeDlWcCs2RU9hWTljYUtcL1VaeXVGa0pYdXRFOTZRcTN4In0%3D